University of Colorado School of Medicine, Aurora, Colorado, USA.
Colorado School of Public Health, Aurora, Colorado, USA.
J Infect Dis. 2022 Apr 19;225(8):1477-1481. doi: 10.1093/infdis/jiab580.
We compared glycoprotein E (gE)- and varicella zoster virus (VZV)-specific Th1 immunity in 160 adults, aged 50-85 years, randomized to receive live or recombinant zoster vaccine (RZV). gE-specific responses measured by interferon-γ (IFN-γ) and interleukin 2 (IL-2) dual-color Fluorospot were significantly higher at all time points postimmunization in RZV recipients. VZV-specific IL-2+ memory, but not IFN-γ+ or IFN-γ+IL-2+ effector responses, were higher in RZV recipients at ≥3 months postimmunization. Only RZV recipients maintained higher postvaccination gE-specific IL-2+ and IFN-γ+ and VZV-specific IL-2+ responses for 5 years. The 5-year persistence of VZV-specific memory and gE-specific Th1 immunity may underlie superior RZV efficacy. Clinical Trials Registration NCT02114333.
我们比较了 160 名年龄在 50-85 岁的成年人的糖蛋白 E（gE）和水痘带状疱疹病毒（VZV）特异性 Th1 免疫，这些成年人被随机分配接受活疫苗或重组带状疱疹疫苗（RZV）。在免疫后所有时间点，RZV 接受者的 gE 特异性反应通过干扰素-γ（IFN-γ）和白细胞介素 2（IL-2）双色 Fluorospot 测量，均显著更高。在免疫后≥3 个月时，RZV 接受者的 VZV 特异性 IL-2+记忆，但不是 IFN-γ+或 IFN-γ+IL-2+效应反应更高。只有 RZV 接受者在 5 年内维持更高的疫苗接种后 gE 特异性 IL-2+和 IFN-γ+和 VZV 特异性 IL-2+反应。VZV 特异性记忆和 gE 特异性 Th1 免疫的 5 年持续存在可能是 RZV 疗效优越的基础。临床试验注册 NCT02114333。
